Loading...
XJPX4516
Market cap1.71bUSD
Dec 27, Last price  
4,007.00JPY
1D
1.93%
1Q
5.03%
Jan 2017
-30.43%
Name

Nippon Shinyaku Co Ltd

Chart & Performance

D1W1MN
XJPX:4516 chart
P/E
10.44
P/S
1.82
EPS
383.67
Div Yield, %
2.97%
Shrs. gr., 5y
—
Rev. gr., 5y
5.26%
Revenues
148.26b
+2.83%
54,254,000,00053,957,000,00056,321,000,00059,439,000,00063,046,000,00062,955,000,00063,550,000,00067,304,000,00069,941,000,00076,517,000,00079,991,000,00084,209,000,00098,781,000,000101,448,000,000114,716,000,000116,637,000,000121,885,000,000137,484,000,000144,175,000,000148,255,000,000
Net income
25.85b
+13.32%
5,639,000,0001,611,000,0002,899,000,0004,030,000,0004,499,000,0004,096,000,0003,958,000,0003,715,000,0004,647,000,0005,750,000,0005,882,000,0006,340,000,00011,749,000,00012,953,000,00016,302,000,00016,866,000,00019,540,000,00024,986,000,00022,812,000,00025,851,000,000
CFO
16.29b
-37.76%
2,804,000,0003,402,000,0004,200,000,0007,346,000,0006,370,000,0009,225,000,0003,233,000,0003,658,000,0003,767,000,0006,015,000,0006,113,000,0008,915,000,00018,916,000,0006,719,000,00015,310,000,00012,737,000,00021,388,000,00021,316,000,00026,170,000,00016,289,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 07, 2025

Profile

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
URL
https://www.nippon-shinyaku.co.jp/
IPO date
Jul 04, 1949
Employees
2,186
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
148,255,000
2.83%
144,175,000
4.87%
137,484,000
12.80%
Cost of revenue
116,869,000
120,838,000
110,750,000
Unusual Expense (Income)
NOPBT
31,386,000
23,337,000
26,734,000
NOPBT Margin
21.17%
16.19%
19.45%
Operating Taxes
7,762,000
7,669,000
8,303,000
Tax Rate
24.73%
32.86%
31.06%
NOPAT
23,624,000
15,668,000
18,431,000
Net income
25,851,000
13.32%
22,812,000
-8.70%
24,986,000
27.87%
Dividends
(8,011,000)
(7,809,000)
(6,799,000)
Dividend yield
2.66%
1.99%
1.21%
Proceeds from repurchase of equity
(1,000)
(2,000)
BB yield
0.00%
0.00%
Debt
Debt current
1,720,000
1,516,000
1,494,000
Long-term debt
4,024,000
3,812,000
3,932,000
Deferred revenue
(5,815,000)
Other long-term liabilities
4,382,000
5,189,000
5,811,000
Net debt
(98,446,000)
(90,457,000)
(84,522,000)
Cash flow
Cash from operating activities
16,289,000
26,170,000
21,316,000
CAPEX
(5,058,000)
(11,728,000)
(8,943,000)
Cash from investing activities
(9,921,000)
(17,631,000)
(10,037,000)
Cash from financing activities
(9,719,000)
(9,605,000)
(8,407,000)
FCF
11,105,000
12,575,000
3,466,000
Balance
Cash
68,703,000
71,601,000
65,740,000
Long term investments
35,487,000
24,184,000
24,208,000
Excess cash
96,777,250
88,576,250
83,073,800
Stockholders' equity
218,569,000
381,538,000
351,361,000
Invested Capital
131,010,750
103,261,750
103,211,200
ROIC
20.17%
15.18%
21.21%
ROCE
13.78%
11.81%
14.35%
EV
Common stock shares outstanding
67,352
67,352
67,353
Price
4,470.00
-23.33%
5,830.00
-30.01%
8,330.00
1.22%
Market cap
301,063,440
-23.33%
392,662,160
-30.01%
561,050,490
1.22%
EV
202,927,440
490,084,160
649,271,490
EBITDA
36,409,000
28,378,000
31,322,000
EV/EBITDA
5.57
17.27
20.73
Interest
329,000
136,000
119,000
Interest/NOPBT
1.05%
0.58%
0.45%